N-oxide 3,4- dihydro- 2,2- dimethyl- 6- nitro- 4- (2- pyridinyl)- 2H-1,4-benzoxazine

structure given in first source; a potassium channel opener

Also Known As:

2H-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, N-oxide; 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide; YM 934; YM-934; YM934

Networked: 8 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198

Experts

1.	Ishikawa, Kimito: 1 article (05/2005)
2.	Masuda, Noriyuki: 1 article (05/2005)
3.	Ohtsuka, Sadanori: 1 article (05/2005)
4.	Suzuki, Shoji: 1 article (05/2005)
5.	Uchida, Wataru: 1 article (05/2005)
6.	Yamaguchi, Iwao: 1 article (05/2005)

Related Diseases

1.	Myocardial Infarction 08/01/1999 - "Reduction by ATP-sensitive potassium channel opener, YM934, of experimental myocardial infarct size in anesthetized dogs." 08/01/1999 - "The present study was undertaken to examine whether the ATP-sensitive potassium channel opener, YM934, would be effective in reducing infarct size in a model of myocardial infarction in anesthetized dogs. " 08/01/1999 - "Infusion of YM934 (0.1 microg/kg/min i.c.) during the last 15 min of pre-ischemia reduced the myocardial infarct size and attenuated the release of creatine kinase MB eluted from the hearts without alteration in hemodynamic parameters including regional myocardial blood flow. "
2.	Infarction (Infarctions) 08/01/1999 - "The present study was undertaken to examine whether the ATP-sensitive potassium channel opener, YM934, would be effective in reducing infarct size in a model of myocardial infarction in anesthetized dogs. "
3.	Pathologic Constriction (Stenosis) 05/01/2005 - "YM934 administration significantly increased LCx flow in the presence of LCx stenosis, (P < 0.05), whereas NTG infusion did not. " 05/01/2005 - "However, LCx peripheral pressure decreased after the induction of stenosis (P < 0.05) and showed no response to either NTG or YM934. " 05/01/2005 - "The measurements were recorded under three study conditions: (1) at baseline without LCx stenosis; (2) with LCx stenosis under NTG infusion (3 microg/Kg/min); and (3) with LCx stenosis after intravenous administration of YM934 (0.3 microg/kg). "
4.	Ischemia 11/01/1999 - "The results suggest that YM934 is capable of attenuating ischemia/reperfusion injury of isolated perfused hearts due to preservation of mitochondrial function during ischemia, probably through opening of mitochondrial K(ATP) channels." 08/01/1999 - "Infusion of YM934 (0.1 microg/kg/min i.c.) during the last 15 min of pre-ischemia reduced the myocardial infarct size and attenuated the release of creatine kinase MB eluted from the hearts without alteration in hemodynamic parameters including regional myocardial blood flow. " 11/01/1999 - "We examined a possible mechanism of action of an ATP-sensitive potassium (K(ATP)) channel opener, YM934, for the improvement of energy metabolism in hearts subjected to 35-min ischemia and 60-min reperfusion. "
5.	Neurogenic Inflammation 11/01/1994 - "These results indicate that YM 934 inhibits airway neurogenic inflammation by modulating the release of neuropeptides from the sensory nerve endings, and that the inhibitory effect can be attributed to the potassium channel opening activity of this compound."

Related Drugs and Biologics

1.	KATP Channels
2.	Potassium Channels (Potassium Channel)
3.	Neuropeptides
4.	Adenosine Triphosphate (ATP)
5.	MB Form Creatine Kinase
6.	Cromakalim (Levcromakalim)
7.	Methacholine Chloride (Methacholine)
8.	Theophylline (Theon)
9.	Bovine Serum Albumin
10.	Potassium

Related Therapies and Procedures

1.	Intravenous Administration
2.	Oral Administration